Remedent, Inc., through its subsidiaries, researches, designs, develops, manufactures, and distributes oral care and cosmetic dentistry products. It primarily provides professional veneers and teeth whitening products for professional and over-the-counter use. The company offers River8, a prefab veneer that enables the dentist to find the right combination of teeth for a patient with minor reshaping. It also provides GlamSmile veneers, which are ultra-thin claddings attached to the front of the patient's teeth leaving the patient's healthy tooth structure intact. In addition, the company offers SmileMe Mirror, an integrated marketing concept for the dental practice, which enables dentists to offer smile consultation in approximately 10 minutes; SmileSketch, a simulation software to make a sketch of what the patient could look like; and various Treatment Pages to explain the benefits of certain treatments, as well as Condor, an intra-oral 3D scanner. It sells its products to dental professionals in approximately 30 countries, including Europe, Asia, Latin America, the Pacific Rim, the Middle East, and the United States through dealers, as well as directly to the consumers through its internal sales force and third party distributors. The company was founded in 1986 and is headquartered in Ghent, Belgium.
Industry, Sector and Symbol
Stock Exchange OTCMKTS
Industry Dental equipment & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:REMI
Previous Symbol
CUSIPN/A
Phone011-32-9241-5880
Debt
Debt-to-Equity RatioN/A
Current Ratio0.71
Quick Ratio0.66
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.70 million
Price / Sales1.48
Cash Flow$0.0023 per share
Price / Cash88.87
Book Value$0.17 per share
Price / Book1.18
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-50,000.00
Net Margins-11.77%
Return on Equity-8.39%
Return on Assets-5.28%
Miscellaneous
Employees12
Outstanding Shares20,000,000
Market Cap$4 million
OptionableNot Optionable
Remedent (OTCMKTS:REMI) Frequently Asked Questions
What is Remedent's stock symbol?
Remedent trades on the OTCMKTS under the ticker symbol "REMI."
Has Remedent been receiving favorable news coverage?
News articles about REMI stock have trended somewhat positive this week, according to InfoTrie. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Remedent earned a media sentiment score of 1.8 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future.
Who are some of Remedent's key competitors?
Who are Remedent's key executives?
Remedent's management team includes the folowing people:
- Mr. Guy De Vreese, Chairman, CEO, CEO of Remedent NV and Pres of Remedent NV (Age 63)
- Mr. Philippe Van Acker, CFO, Chief Accounting Officer, Controller & Director (Age 53)
- Mr. Mark E. Sernatinger, Exec. Officer of United States Office
- Mr. Scott G. Juhl, Exec. Officer of United States Office
- Mr. Stacey J. Ammons, Exec. Officer of United States Office
How do I buy shares of Remedent?
Shares of REMI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Remedent's stock price today?
One share of REMI stock can currently be purchased for approximately $0.20.
How big of a company is Remedent?
Remedent has a market capitalization of $4 million and generates $2.70 million in revenue each year. Remedent employs 12 workers across the globe.
What is Remedent's official website?
How can I contact Remedent?
Remedent's mailing address is BELGIUM ZUIDERLAAN 1-3 BUS 8, GHENT C9, 9000. The company can be reached via phone at 011-32-9241-5880.
MarketBeat Community Rating for Remedent (OTCMKTS REMI)
MarketBeat's community ratings are surveys of what our community members think about Remedent and other stocks. Vote "Outperform" if you believe REMI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REMI will underperform the S&P 500 over the long term. You may vote once every thirty days.
